VPS75 Antibody

What is VPS75 and why is it significant in epigenetic research?

VPS75 (Vacuolar Protein Sorting 75) is a histone chaperone belonging to the Nap1 family that forms a complex with the histone acetyltransferase Rtt109. This complex plays a crucial role in regulating histone H3 acetylation, particularly at lysines K9 and K27 within canonical histone (H3-H4)₂ tetramers . VPS75 is particularly significant in epigenetic research because it demonstrates functional specificity in activating Rtt109, despite structural homology with other histone chaperones like Nap1 .

The significance of VPS75 extends beyond its role as a cofactor for Rtt109, as it also has independent functions in transcription-associated histone exchange . Understanding VPS75 provides valuable insights into chromatin regulation mechanisms that govern gene expression, DNA replication, and DNA repair pathways, making it a crucial target for epigenetic studies and potential therapeutic interventions in fungal pathogens like Pneumocystis carinii .

How does VPS75 differ from other histone chaperones in the NAP1 family?

• Functional specificity: Only VPS75 can effectively stimulate Rtt109 HAT activity, despite Nap1's ability to bind both histones and Rtt109 with similar affinities .

• Phenotypic consequences: Deletion of VPS75 results in "dramatic and diverse mutant phenotypes," whereas deletion of NAP1 has minimal observable effects .

• Structural domains: VPS75 possesses a flexible C-terminal acidic domain that is critical for both its in vivo functions and modulation of Rtt109 activity in vitro .

• Transcriptional roles: VPS75 has Rtt109-independent functions in transcription-associated processes, as evidenced by its genetic interactions with transcription factors like TFIIS and components of the RNAPII machinery .

These functional differences highlight the evolutionary specialization of VPS75 for specific roles in chromatin regulation despite structural similarities to other Nap1 family members.

What are the known structural conformations of VPS75 that antibodies might recognize?

VPS75 exists in multiple structural conformations that should be considered when selecting or developing antibodies:

• Dimeric form: VPS75 forms obligate homodimers through the antiparallel pairing of long α2 helices . This dimeric conformation is functionally important as it directly interacts with histone (H3-H4)₂ tetramers to regulate H3K9 and H3K27 acetylation, rather than forming a Vps75-Rtt109 complex .

• Tetrameric form: VPS75 can also assemble into tetramers where the major histone-binding surface is buried within a "walnut-like structure" when not bound to histone cargo . This conformational change may mask certain epitopes.

• Complex with Rtt109: When in complex with Rtt109, VPS75 adopts a conformation that enables efficient catalysis of histone acetylation .

• Histone-bound state: The interaction with histones may induce conformational changes in VPS75, particularly involving its C-terminal acidic domain .

• Free state with exposed C-terminal domain: The flexible C-terminal acidic domain (residues 224-250 in P. carinii Vps75) is disordered and contributes to histone interactions .

Researchers should carefully consider which conformation(s) they wish to target with antibodies, as epitope accessibility may vary significantly between these structural states.

What are the optimal conditions for using VPS75 antibodies in chromatin immunoprecipitation (ChIP) experiments?

For successful ChIP experiments using VPS75 antibodies, consider the following methodological approach:

• Cross-linking conditions: Standard formaldehyde cross-linking (1% for 10 minutes at room temperature) is typically sufficient for VPS75 ChIP, as it effectively captures both protein-DNA and protein-protein interactions .

• Sonication parameters: Aim for chromatin fragments of 200-500 bp for optimal resolution of VPS75 binding sites. This typically requires 10-15 cycles of sonication (30 seconds on/30 seconds off) using a Bioruptor or similar device .

• Antibody selection and validation:

  • Use monoclonal antibodies against tagged versions of VPS75 (e.g., 9E10 antibody against Myc-tagged VPS75) for high specificity

  • Validate antibody specificity using western blot and immunoprecipitation with wild-type and vps75Δ strains

  • For native VPS75, ensure the antibody does not cross-react with structurally similar proteins like Nap1

• Controls and normalization:

  • Include input samples, IgG controls, and non-transcribed regions (e.g., telomeric DNA) for normalization

  • Compare signals to untagged strains when using antibodies against tagged proteins

  • Include vps75Δ strains as negative controls

• Data analysis: Calculate enrichment by dividing the amount of precipitated DNA by the input sample and correct against a non-transcribed region and, when applicable, the equivalent signal from an untagged strain .

For genome-wide distribution analysis (ChIP-chip or ChIP-seq), ensure sufficient sequencing depth (>10 million reads) to capture the dynamic range of VPS75 binding patterns across the genome .

How should researchers optimize western blot protocols specifically for VPS75 detection?

Optimizing western blot protocols for reliable VPS75 detection requires attention to several technical parameters:

• Sample preparation:

  • Use a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, and protease inhibitors

  • Include phosphatase inhibitors if studying VPS75 phosphorylation

  • Heat samples at 65°C instead of boiling to prevent aggregation of this histone chaperone

• Gel conditions:

  • Use 10-12% SDS-PAGE gels for optimal resolution of VPS75 (~30 kDa)

  • Consider gradient gels (4-15%) when detecting VPS75 complexes with Rtt109 or histones

  • Use MOPS running buffer for better resolution of acidic proteins like VPS75

• Transfer parameters:

  • Semi-dry transfer: 15V for 30 minutes

  • Wet transfer: 100V for 1 hour or 30V overnight at 4°C

  • Use PVDF membranes (0.45 μm) for stronger protein binding

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Primary antibody dilution: 1:1000-1:5000 in 5% BSA in TBST, overnight at 4°C

  • Secondary antibody dilution: 1:5000-1:10000 in 5% milk in TBST, 1 hour at room temperature

• Detection considerations:

  • For low abundance samples, use enhanced chemiluminescence (ECL) plus or femto substrates

  • Fluorescent secondary antibodies may provide better quantitative analysis

  • Strip and reprobe for histone H3 as a loading control when analyzing chromatin fractions

When comparing wild-type and mutant VPS75 variants (e.g., those with altered C-terminal acidic domains), adjust sample loading to account for potential differences in expression levels .

What controls are essential when validating a new VPS75 antibody for research applications?

Comprehensive validation of a new VPS75 antibody requires multiple control experiments:

• Genetic controls:

  • vps75Δ strain comparison: No signal should be detected in samples from strains where VPS75 has been deleted

  • Overexpression system: Enhanced signal should correlate with increased VPS75 expression

  • Tagged VPS75 strains: Parallel detection with both anti-tag and anti-VPS75 antibodies should show matching signals

• Biochemical specificity:

  • Western blot analysis against recombinant VPS75 and whole cell extracts

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Competitive binding assays with purified VPS75 protein to demonstrate specific inhibition

• Cross-reactivity assessment:

  • Test against purified Nap1 protein (24% sequence homology with VPS75)

  • Evaluate detection in samples containing other NAP family proteins

  • Perform immunoblotting in species with varying degrees of VPS75 conservation

• Epitope accessibility:

  • Compare detection of VPS75 in different conformational states (dimeric, tetrameric, Rtt109-bound)

  • Test antibody performance under native and denaturing conditions

  • Evaluate detection of free VPS75 versus chromatin-bound fractions

• Application-specific validation:

  • For ChIP applications: Perform ChIP-qPCR at known VPS75-bound loci

  • For immunofluorescence: Compare staining patterns to GFP-tagged VPS75 localization

  • For immunoprecipitation: Verify co-precipitation of known interactors like Rtt109

Document all validation steps thoroughly, including antibody concentration, incubation conditions, and detection methods to ensure reproducibility.

How can researchers distinguish between the different functional roles of VPS75 when using antibodies in experiments?

To differentiate between VPS75's roles as a Rtt109 cofactor versus its independent functions in transcription, researchers can employ several strategic approaches:

• Genetic background manipulation:

  • Perform experiments in rtt109Δ backgrounds to isolate Rtt109-independent functions of VPS75

  • Use strains expressing mutant VPS75 variants that selectively disrupt specific interactions (e.g., VPS75 with impaired histone binding but intact Rtt109 interaction)

  • Combine VPS75 antibody studies with H3K9ac and H3K56ac detection to correlate with HAT-dependent functions

• Temporal resolution techniques:

  • Conduct ChIP-seq time course experiments during transcriptional induction (e.g., galactose induction of GAL10) to track the kinetics of VPS75 recruitment relative to RNAPII and histone modifications

  • Use rapid inducible protein degradation systems (e.g., auxin-inducible degrons) to acutely deplete VPS75 and monitor immediate consequences on transcription versus HAT activity

• Spatial distribution analysis:

  • Compare VPS75 localization at promoters versus gene bodies to differentiate roles in transcription initiation versus elongation

  • Analyze co-occupancy with transcription factors (TFIIS, Elongator) versus histone modification machinery

  • Perform sequential ChIP (re-ChIP) to identify subpopulations of VPS75 that are specifically associated with Rtt109 versus transcription machinery

• Functional readouts:

  • Measure 5':3' RNA ratios at various genes in vps75Δ versus wild-type strains to assess elongation defects

  • Compare transcriptome profiles (RNA-seq) in various genetic backgrounds (vps75Δ, rtt109Δ, vps75Δ rtt109Δ)

  • Assess sensitivity to transcription elongation inhibitors (6-azauracil) versus genotoxic agents that affect replication

• Biochemical separation:

  • Fractionate cellular extracts to separately analyze chromatin-bound, nucleoplasmic, and Rtt109-associated pools of VPS75

  • Use size exclusion chromatography to distinguish free VPS75 dimers/tetramers from Rtt109-bound complexes

These approaches allow researchers to parse the multiple roles of VPS75 and determine which functions are being detected in specific experimental contexts.

What are the critical considerations when designing experiments to study the interaction between VPS75 and Rtt109?

Designing robust experiments to investigate VPS75-Rtt109 interactions requires careful attention to multiple factors:

• Protein conformational states:

  • Account for different oligomeric states of VPS75 (dimers and tetramers) that may affect interaction with Rtt109

  • Consider the impact of histone binding on VPS75-Rtt109 complex formation

  • Use chemical crosslinking methods that preserve transient or dynamic interactions

• Domain-specific contributions:

  • Target the C-terminal acidic domain (residues 224-250 in P. carinii Vps75) that influences Rtt109 activation

  • Consider the acidic patch (residues 192E, 193D, 194E, 195E, and 196E) that mediates histone interactions and impacts Rtt109-mediated acetylation

  • Design constructs with specific domain deletions or mutations to dissect functional contributions

• Functional readouts:

  • Incorporate HAT activity assays to assess functional consequences of interactions

  • Compare acetylation of different histone residues (H3K9, H3K27, H3K56) that have varying dependencies on VPS75

  • Include cellular phenotype analyses (growth under genotoxic stress)

• Species-specific variations:

  • Account for structural and functional differences between species (e.g., S. cerevisiae versus P. carinii Vps75)

  • Consider evolutionary conservation when designing mutation studies

  • Use homology modeling when structural data for specific species is unavailable

• Technical approach diversification:

  • Combine in vitro biochemical assays (pull-downs, surface plasmon resonance) with in vivo approaches (co-immunoprecipitation, FRET)

  • Validate protein-protein interactions using orthogonal methods

  • Consider proximity labeling approaches (BioID, APEX) to capture transient interactions in cellular contexts

• Quantitative analysis:

  • Determine binding affinities and kinetic parameters for different interaction partners

  • Use concentration gradients to identify stoichiometric requirements

  • Apply mathematical modeling to integrate multiple interaction parameters

How does VPS75 antibody performance differ when studying its role in DNA damage response versus transcriptional regulation?

VPS75 antibody performance can vary significantly between DNA damage response and transcriptional regulation studies due to context-specific factors:

• Protein abundance differences:

  • VPS75 recruitment increases at sites of DNA damage and actively transcribed genes

  • Higher local concentrations at induced genes may require antibody dilution optimization

  • DNA damage sites may have more complex protein assemblies that could mask epitopes

• Chromatin state variations:

  • Transcriptionally active regions have more accessible chromatin, potentially improving antibody access

  • DNA damage sites involve compacted chromatin and repair machinery that may interfere with antibody binding

  • Crosslinking conditions may need optimization for different chromatin contexts

• Post-translational modifications:

  • VPS75 may undergo different modifications in response to DNA damage versus transcriptional activation

  • Phosphorylation events during DNA damage response could affect epitope recognition

  • Antibodies raised against unmodified VPS75 may show reduced affinity for modified forms

• Cofactor associations:

  • During transcription, VPS75 interacts with elongation factors and RNAPII

  • In DNA repair, VPS75-Rtt109 complexes associate with repair machinery

  • These different protein-protein interactions may mask or alter epitope accessibility

• Experimental approach adaptations:

  • For DNA damage studies: Use shorter crosslinking times and gentler sonication

  • For transcription studies: Consider nascent RNA isolation in parallel to correlate with VPS75 binding

  • For both contexts: Employ sequential ChIP to identify specific subpopulations

Research outcomes from studies examining these distinct roles should be interpreted with awareness of these technical considerations, and optimization should be performed for each specific experimental context.

How should researchers interpret contradictory findings between ChIP-seq and biochemical assays for VPS75 function?

When facing discrepancies between ChIP-seq and biochemical data regarding VPS75 function, consider the following analytical framework:

• Nature of the assays:

  • ChIP-seq captures in vivo chromatin associations in a cellular context

  • Biochemical assays (e.g., HAT assays, nucleosome disassembly) measure isolated activities in controlled environments

  • These fundamental differences may explain apparently contradictory results

• Context-dependent functions:

  • VPS75 has distinct roles in different cellular processes (transcription vs. DNA replication/repair)

  • Genetic evidence indicates that VPS75 and Rtt109 have different functional profiles despite their physical association (CC = -0.38)

  • Consider whether the contradiction reflects true biological complexity rather than technical artifacts

• Methodological considerations:

  • ChIP efficiency depends on epitope accessibility, which may vary across chromatin contexts

  • Different fixation methods may preferentially capture certain interactions

  • Biochemical assays may not recapitulate the full complexity of cellular cofactors and conditions

• Reconciliation strategies:

  • Perform ChIP-reChIP to identify specific subpopulations of VPS75 with distinct functions

  • Use spike-in controls to ensure quantitative comparability across ChIP experiments

  • Examine genetic dependencies by conducting experiments in various mutant backgrounds

  • Develop targeted biochemical assays that better mimic the cellular environment

• Data integration approaches:

  • Apply computational methods to integrate multiple data types

  • Construct network models that accommodate apparently contradictory roles

  • Examine time-resolution data to determine whether functions occur sequentially

The apparent contradiction that VPS75 deletion has minor effects on global H3K56 acetylation despite its role in stimulating Rtt109 activity exemplifies this issue and suggests redundant or context-specific functions that may not be captured by individual assays .

What are the common pitfalls when measuring VPS75-dependent histone acetylation, and how can they be avoided?

Measuring VPS75-dependent histone acetylation presents several challenges that require careful experimental design:

• Redundancy with other histone chaperones:

  • VPS75 deletion has minor effects on global H3K56ac despite its role in stimulating Rtt109

  • Asf1 may compensate for VPS75 loss in vivo

  • Solution: Use double mutants (vps75Δ asf1Δ) to overcome redundancy or conduct site-specific rather than global analyses

• Specificity of acetylation sites:

  • Rtt109 acetylates multiple lysines (H3K9, H3K27, H3K56) with different dependencies on VPS75

  • Gcn5 also acetylates H3K9, potentially confounding results

  • Solution: Use site-specific antibodies validated for selectivity and specificity; incorporate appropriate genetic controls (gcn5Δ, rtt109Δ)

• Technical variability in acetylation detection:

  • Western blot quantification may lack sensitivity for subtle changes

  • ChIP efficiency varies between antibodies targeting different modifications

  • Solution: Use quantitative methods (mass spectrometry) for absolute quantification; normalize to total histone H3 levels

• Dynamic nature of acetylation:

  • Acetylation is constantly added and removed by HATs and HDACs

  • Cell cycle phase affects acetylation patterns, particularly for replication-linked modifications

  • Solution: Synchronize cells when appropriate; conduct time-course experiments; consider HDAC inhibitor treatments as controls

• Influence of experimental conditions:

  • In vitro HAT assays may not reflect in vivo activity

  • Buffer composition significantly impacts enzymatic activity

  • Solution: Include physiological concentrations of competing factors; validate in vitro findings with cellular experiments

• Quantification challenges:

  • Signal saturation in immunoblots can mask differences

  • Background subtraction methods affect data interpretation

  • Solution: Use standard curves with recombinant acetylated histones; employ multiple antibody dilutions to ensure linear detection range

How can VPS75 antibodies be used to distinguish between its dimeric and tetrameric forms in experimental settings?

Differentiating between dimeric and tetrameric forms of VPS75 requires specialized experimental approaches:

• Native gel electrophoresis:

  • Use native PAGE to separate oligomeric forms based on size and charge

  • Optimize gel percentage (6-8%) for separation of dimers (~60 kDa) from tetramers (~120 kDa)

  • Follow with western blotting using VPS75 antibodies

  • Critical control: Include recombinant VPS75 dimers and tetramers as migration standards

• Crosslinking approaches:

  • Apply mild chemical crosslinking (e.g., 0.01-0.1% glutaraldehyde) to stabilize oligomeric states

  • Separate crosslinked products via SDS-PAGE

  • Detect with VPS75 antibodies via western blot

  • Optimization tip: Titrate crosslinker concentration and reaction time to prevent artificial aggregation

• Size exclusion chromatography with immunodetection:

  • Fractionate cell extracts by size using Superose 6 or Superdex 200 columns

  • Analyze fractions by western blotting with VPS75 antibodies

  • Compare elution profiles with known molecular weight standards

  • Integration approach: Combine with multi-angle light scattering (SEC-MALS) for absolute molecular weight determination

• Conformation-specific antibodies:

  • Develop antibodies that specifically recognize epitopes exposed only in dimeric or tetrameric forms

  • Target the "walnut-like structure" interface that becomes buried in tetramers

  • Validate specificity using recombinant proteins of known oligomeric state

  • Application: Use in immunoprecipitation to selectively pull down specific oligomeric forms

• Proximity-based approaches:

  • Implement FRET with differentially tagged VPS75 constructs

  • Higher FRET efficiency would indicate tetrameric forms due to closer proximity

  • Analyze by flow cytometry or microscopy for population or single-cell resolution

  • Consideration: Ensure tags do not disrupt natural oligomerization

• Functional correlation:

  • PcVps75 dimers interact directly with histone (H3-H4)₂ tetramers

  • Tetramers have the major histone-binding surface buried

  • Correlate oligomeric state with histone binding and Rtt109 activation

  • Experimental design: Compare wild-type VPS75 with mutants that disrupt tetramerization but preserve dimerization

These methods can be combined to provide complementary evidence for the presence and functional significance of different VPS75 oligomeric states in various experimental settings.

How might advances in super-resolution microscopy change our understanding of VPS75 localization and function?

Super-resolution microscopy offers unprecedented insights into VPS75 spatial organization that could transform our understanding of its functions:

• Nuclear microenvironment mapping:

  • Traditional microscopy cannot resolve the fine-scale distribution of VPS75 within the nucleus

  • Super-resolution techniques (STORM, PALM, STED) can achieve 20-50 nm resolution

  • This allows visualization of VPS75 clusters at specific genomic loci rather than diffuse signals

  • Potential finding: VPS75 may form discrete foci at replication origins or transcription factories

• Dynamic interaction visualization:

  • Single-molecule tracking can monitor individual VPS75 molecules in living cells

  • This reveals dwelling times at chromatin and protein-protein interaction dynamics

  • Time-resolved imaging during DNA damage or transcriptional induction captures response kinetics

  • Methodological approach: Implement PALM with photoactivatable fluorescent protein-tagged VPS75

• Multi-protein complex architecture:

  • Multi-color super-resolution imaging can determine the spatial relationship between VPS75, Rtt109, and chromatin

  • This reveals whether complexes form before or after chromatin binding

  • Expansion microscopy provides enhanced resolution of molecular assemblies

  • Technical consideration: Use site-specific labeling strategies to minimize functional interference

• Chromatin domain association:

  • Correlative light and electron microscopy (CLEM) can relate VPS75 distribution to chromatin ultrastructure

  • This distinguishes associations with euchromatin versus heterochromatin domains

  • 3D-STORM imaging provides volumetric context for VPS75 localization patterns

  • Research implication: May reveal preferential association with particular chromatin environments

• Cell cycle-dependent reorganization:

  • 4D imaging (3D + time) can track VPS75 redistribution throughout the cell cycle

  • This connects localization patterns to known functions in replication and transcription

  • Stimulated emission depletion (STED) microscopy offers the temporal resolution needed to capture rapid dynamics

  • Potential discovery: VPS75 may show distinct localization patterns during S-phase versus other cell cycle phases

These advanced imaging approaches will require careful optimization of fixation protocols, antibody access, and fluorophore selection to maintain epitope recognition while achieving the resolution necessary to answer these fundamental questions about VPS75 biology.

What are the implications of studying VPS75 as a potential therapeutic target in pathogenic fungi?

Exploring VPS75 as a therapeutic target in pathogenic fungi presents several promising avenues for antifungal development:

• Selective targeting potential:

  • Rtt109-VPS75 represents a fungal-specific HAT complex with no direct homologs in humans

  • This offers a potentially wide therapeutic window for selective toxicity

  • Structure-based drug design can exploit unique features of the fungal VPS75-Rtt109 interface

  • Research priority: Perform comparative analysis of VPS75 across pathogenic fungi to identify conserved targetable features

• Vulnerability in Pneumocystis carinii:

  • P. carinii causes life-threatening pneumonia in immunocompromised patients

  • PcVps75-PcRtt109 interaction is critical for H3K9/H3K27 acetylation and cellular growth under genotoxic stress

  • Disrupting this interaction could sensitize the pathogen to host defense mechanisms or existing antifungals

  • Experimental approach: Screen for small molecules that disrupt PcVps75-histone interactions using the identified acidic patch (residues 192-196) as a target

• Combination therapy potential:

  • VPS75 inhibition sensitizes cells to genotoxic agents that block DNA replication

  • This suggests synergistic potential with existing antifungals that induce DNA damage

  • Targeting multiple pathways simultaneously may reduce resistance development

  • Clinical consideration: Develop assays to predict effective drug combinations based on VPS75 status

• Biomarker applications:

  • VPS75 expression or post-translational modification patterns may predict antifungal responsiveness

  • Monitoring VPS75-dependent acetylation could serve as a pharmacodynamic marker in drug development

  • VPS75 antibodies could be developed for diagnostic applications in fungal infections

  • Diagnostic development: Create sensitive assays for detecting VPS75 or its activity in clinical specimens

• Structural considerations for drug design:

  • The different oligomeric states of VPS75 (dimers vs. tetramers) offer multiple targeting opportunities

  • Small molecules could either stabilize the tetrameric form (where histone-binding surfaces are buried) or prevent dimer-tetramer transitions

  • Peptide-based inhibitors could mimic the C-terminal acidic domain to compete for histone binding

  • Structure-activity relationship focus: Develop compounds that specifically disrupt the electrostatic interactions between PcVps75's acidic residues and histones

These research directions highlight the translational potential of fundamental studies on VPS75 biology in addressing the growing clinical challenge of fungal infections, particularly in immunocompromised populations.